Medical equipment – Canon Printer Help Desk http://canonprinterhelpdesk.com/ Tue, 22 Nov 2022 14:30:21 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://canonprinterhelpdesk.com/wp-content/uploads/2021/06/icon-2021-06-29T185907.604.png Medical equipment – Canon Printer Help Desk http://canonprinterhelpdesk.com/ 32 32 Tonawanda cardiac arrest survivor meets paramedic who saved his life https://canonprinterhelpdesk.com/tonawanda-cardiac-arrest-survivor-meets-paramedic-who-saved-his-life/ Tue, 22 Nov 2022 14:11:00 +0000 https://canonprinterhelpdesk.com/tonawanda-cardiac-arrest-survivor-meets-paramedic-who-saved-his-life/ This would not have been possible without medical equipment that few agencies have. TONAWANDA, NY – A Tonawanda man meets the paramedic who saved his life. This would not have been possible without medical equipment that few agencies have. The first time Jay Napieralski and Kerry Riley met was seven years ago during an emergency. […]]]>

This would not have been possible without medical equipment that few agencies have.

TONAWANDA, NY – A Tonawanda man meets the paramedic who saved his life. This would not have been possible without medical equipment that few agencies have.

The first time Jay Napieralski and Kerry Riley met was seven years ago during an emergency.

“My wife woke up in the middle of the night to find me unresponsive and called 911,” Riley said.

Riley was having a heart attack.

“Tonawanda City paramedics came to the house and resuscitated me,” Riley said.

“We shocked him. I think seven to eight times. Before we got traffic back,” Napieralski said. “There are calls that stay very vivid in your memory and this is one of them.”

Tonawanda City paramedics were among the first in the area to procure specialized equipment called Zoll X custom cabinets. Their agency now has six.

All monitors were donated by the James V and Fay P Ryan Paramedic Foundation, a group started by local paramedics that focuses on getting back to first responders.

This equipment gave Riley another chance.

“Every time I see them I choke. I wouldn’t be here without them,” Riley said.

The foundation also donated a new car and four cyanide antidote kits that few agencies have due to cost.

This equipment saved Riley’s life, but it also saved his twin brother in a way. After his heart attack, his brother discovered through testing that Riley’s health issues were genetic.

The photo above shows Riley’s twin brother on the left and Riley on the right. They are both holding each other’s children.

To find out more about the foundation, you can go to the James V and Fay P Ryan Paramedic Foundation website.

]]>
Nuclear Medicine Equipment Market Size, Share, Opportunities, https://canonprinterhelpdesk.com/nuclear-medicine-equipment-market-size-share-opportunities/ Thu, 17 Nov 2022 05:46:00 +0000 https://canonprinterhelpdesk.com/nuclear-medicine-equipment-market-size-share-opportunities/ Nuclear Medicine Equipment Market Report According to IMARC Group’s latest report, titled “Nuclear Medicine Equipment Market: Global Industry Trends, Share, Size, Growth, Opportunities, and Forecast 2022-2027”, the global nuclear medicine equipment market size has reached $2.7 billion in 2021. Going forward, IMARC Group expects the market to reach US$4 billion by 2027 growing at a […]]]>

Nuclear Medicine Equipment Market Report

According to IMARC Group’s latest report, titled “Nuclear Medicine Equipment Market: Global Industry Trends, Share, Size, Growth, Opportunities, and Forecast 2022-2027”, the global nuclear medicine equipment market size has reached $2.7 billion in 2021. Going forward, IMARC Group expects the market to reach US$4 billion by 2027 growing at a CAGR of 6.8% in the period 2022 -2027.

Report metric
History: 2016-2021
Base year: 2021
Forecast year: 2022-2027

Download a free sample of the report: https://www.imarcgroup.com/nuclear-medicine-equipment-market/requestsample

Nuclear Medicine Equipment Market Industry Definition and Application:

Nuclear medicine equipment refers to medical devices that use radioactive materials or radionuclides to generate anatomical images and record disease progression. Radionuclides represent the cleaning molecules composed with excessive energy used for the manufacture of radiopharmaceuticals. Nuclear medicine equipment is used to examine various biological processes, such as tissue blood flow, cell receptor functioning, metabolism, neurotransmitter activity, and apoptosis. Additionally, they use Single Photon Emission Computed Tomography (SPECT) imaging technologies and specialized gamma cameras to detect movement disorders and several types of dementia. As a result, nuclear medicine equipment finds wide application in the treatment of gastrointestinal, endocrine, oncological, cardiovascular and neurological disorders throughout the world.

As the novel coronavirus (COVID-19) crisis engulfs the world, we continuously monitor changes in markets, as well as industry consumer behaviors around the world and our estimates on the latest market trends and forecasts are made. after considering the impact of this pandemic.

Nuclear Medicine Equipment Market Trends and Drivers:

Rising prevalence of chronic medical conditions and increasing geriatric population that is more prone to age-related and associated diseases are some of the major factors driving the nuclear medicine equipment market. Furthermore, the growing requirement for personalized drugs among patients and healthcare professionals further increases the market growth. Additionally, various technological advancements, including the development of data-integrated imaging systems and radiotracers that allow computer-assisted image reconstruction and processing and accurate recognition of medical conditions to compare diagnostic scans and monitor the progression of a disease, also catalyze the global market. Apart from this, healthcare institutions are moving from stand-alone imaging techniques to hybrid imaging techniques to generate accurate and high-resolution images, which act as important growth factors. In addition, the extensive research and development (R&D) activities in the field of biotechnology and increasing improvements in medical infrastructure, especially in developing economies, are expected to propel the nuclear medicine equipment market during the forecast period.

Browse the full report with TOC: https://www.imarcgroup.com/nuclear-medicine-equipment-market

Nuclear Medicine Equipment Market Segmentation:

Competitive Landscape:

The report has segmented the market based on region, product, application, and end user.

Breakdown by product:

Single photon emission tomography
Autonomous
Hybrid
Positron emission tomography
Autonomous
Hybrid
Planar scintigraphy

Breakdown by application:

Neurology
Oncology
Cardiology
Others

Breakdown by end user:

Hospitals
Imaging centers
Academic and research institutes
Others

Breakdown by region:

North America (USA, Canada)
Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, others)
Middle East and Africa

Who are the key players in the Nuclear Medicine Equipment Market?

The report provides a detailed analysis of market leaders including.

Biodex Medical Systems Inc. (Mirion Technologies Inc.), Cardinal Health Inc., CMR Naviscan Corporation, DDD-Diagnostic A/S, Digirad Corporation, General Electric Company, Koninklijke Philips NV, Mediso Ltd., Neusoft Corporation, Siemens AG, SurgicEye GmbH and Toshiba Corporation.

Related report from the IMARC group:

Behavioral Rehabilitation Market Report: https://www.imarcgroup.com/behavioral-rehabilitation-market

Onychomycosis Treatment Market Report: https://www.imarcgroup.com/onychomycosis-treatment-market

Lateral Flow Testing Market Report: https://www.imarcgroup.com/lateral-flow-assay-market

Formulation Development Outsourcing Market Report: https://www.imarcgroup.com/formulation-development-outsourcing-market

Drug Device Combination Products Market Report: https://www.imarcgroup.com/drug-device-combination-products-market

Nanopore Technology Market Report: https://www.imarcgroup.com/nanopore-technologies-market

Europe DNA Sequencing Products Market Report: https://www.imarcgroup.com/europe-dna-sequencing-products-market

Pyrogen Testing Market Report: https://www.imarcgroup.com/pyrogen-testing-market

IMARC Group
30 N Gould St Ste R
Sheridan, Wyoming 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Such. :(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

The IMARC Group is a leading market research firm providing management strategies and market research worldwide. We partner with clients across all industries and geographies to identify their most important opportunities, address their most critical challenges and transform their businesses.

IMARC’s information products include major business, scientific, economic and technological developments for business leaders in pharmaceutical, industrial and high-tech organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverages, travel and tourism, nanotechnology and new processing methods are at the top of the list. company expertise.

This press release was published on openPR.

]]>
Kherson celebrates Russia’s exit but faces huge reconstruction https://canonprinterhelpdesk.com/kherson-celebrates-russias-exit-but-faces-huge-reconstruction/ Sun, 13 Nov 2022 17:36:39 +0000 https://canonprinterhelpdesk.com/kherson-celebrates-russias-exit-but-faces-huge-reconstruction/ Comment this story Comment KHERSON, Ukraine — Residents of Kherson celebrated the end of eight months of Russian occupation for the third consecutive day on Sunday, even as they took stock of the extensive damage left in the southern Ukrainian city by retreating Kremlin forces. A cheering crowd gathered in Kherson’s main square, despite the […]]]>

Comment

KHERSON, Ukraine — Residents of Kherson celebrated the end of eight months of Russian occupation for the third consecutive day on Sunday, even as they took stock of the extensive damage left in the southern Ukrainian city by retreating Kremlin forces.

A cheering crowd gathered in Kherson’s main square, despite the distant sounds of artillery fire that could be heard as Ukrainian forces continued their efforts to repel the invading force from Moscow.

“It’s a new year for us now,” said Karina Zaikina, 24, who wore a yellow and blue ribbon in Ukraine’s national colors on her coat. “For the first time in many months, I wasn’t afraid to come to town.”

“Finally, freedom!” said Tetiana Hitina, a 61-year-old resident. “The city was dead.

But even as locals rejoiced, evidence of Russia’s ruthless occupation was rife, and Russian forces still control around 70 percent of the wider Kherson region.

With mobile phone networks down, Zaikina and others lined up to use a satellite phone connection set up for the use of all in the square, allowing them to exchange news with family and friends to the first time in weeks.

Downtown stores were closed. With many people having fled the city during the Russian occupation, the streets of the city were sparsely populated. Many of the few who ventured out on Sunday carried yellow and blue flags. In the square, people lined up to ask the soldiers to sign their flags and rewarded them with hugs. Some cried.

Darker still, Kherson is also without electricity or running water, and food and medical supplies are in short supply. Residents said Russian troops looted the town, taking the spoils when they withdrew last week. They also destroyed key public infrastructure before retreating across the wide Dnieper River to its eastern bank. A Ukrainian official described the situation in Kherson as “a humanitarian catastrophe”.

“I don’t understand what kind of people they are. I don’t know why they did it,” said resident Yevhen Teliezhenko, draped in a Ukrainian flag.

Still, he says, “it became easier to breathe” once the Russians left.

“There’s no better holiday than what’s happening now,” he said.

Ukrainian authorities said demining of critical infrastructure was underway in the city. Reconnecting electricity supply is the priority, with gas supply already secured, Kherson regional governor Yaroslav Yanushevych said.

The Russian withdrawal marked a triumphant step in Ukraine’s resistance to the invasion of Moscow nearly nine months ago. Over the past two months, the Ukrainian army claimed to have taken over dozens of towns and villages north of the city of Kherson.

Ukrainian President Volodymyr Zelensky vowed to keep pressure on Russian forces, reassuring residents of Ukrainian towns and villages still under occupation.

“We don’t forget anyone; we will not abandon anyone,” he said.

Ukraine’s recapture of Kherson was a major setback for the Kremlin and the latest in a series of battlefield embarrassments. It came about six weeks after Russian President Vladimir Putin annexed the Kherson region and three other provinces in southern and eastern Ukraine – in violation of international law – and declared them Russian territory.

The U.S. Embassy in Kyiv tweeted comments from National Security Advisor Jake Sullivan on Sunday, who described the turnaround in Kherson as “an extraordinary victory” for Ukraine and “a truly remarkable thing.”

The reversal occurred despite Putin’s recent partial mobilization of reservists, increasing the number of troops by around 300,000. This has been difficult for the Russian military to digest.

“Russia’s military leadership is largely trying and failing to integrate combat forces from many different organizations and many different types and levels of skills and equipment into a more cohesive combat force in Ukraine,” the Institute commented. Washington-based war study. , a think tank that follows the conflict

British Defense Secretary Ben Wallace said the Kremlin would be “worried” about the loss of Kherson, but warned against underestimating Moscow. “If they need more cannon fodder, that’s what they’ll do,” he said.

Ukrainian police have called on residents to help identify collaborators with Russian forces. Ukrainian police returned to the city on Saturday, along with public broadcasting services. Ukraine’s national police chief Ihor Klymenko said around 200 officers were at work in the city, setting up checkpoints and documenting evidence of possible war crimes.

In what could be the next district to fall in Ukraine’s march on territory annexed by Moscow, the Russian-appointed administration of Kakhovka district, east of the city of Kherson, announced on Saturday that she evacuated her employees.

“Today the administration is the number one target of Ukrainian attacks,” said Moscow-based Kakhovka chief Pavel Filipchuk. “We, as an authority, are moving to safer territory, from where we will lead the district.”

Kakhovka is located on the eastern bank of the Dnieper River, upstream from the Kakhovka hydroelectric power station.

John Leicester contributed to this story from Kyiv, Ukraine.

Follow AP’s coverage of the war in Ukraine: https://apnews.com/hub/russia-ukraine

]]>
With an increase in the geriatric population, portable https://canonprinterhelpdesk.com/with-an-increase-in-the-geriatric-population-portable/ Thu, 10 Nov 2022 16:30:00 +0000 https://canonprinterhelpdesk.com/with-an-increase-in-the-geriatric-population-portable/ LONDON, Nov. 10, 2022 (GLOBE NEWSWIRE) — Get 33% off for a limited time on our uniquely designed opportunity and strategy market research reports. Contact us today and develop winning strategies! According The Business Research Company’s research report on hand surgical instruments market, an increase in the geriatric population is driving the handheld surgical instruments […]]]>

LONDON, Nov. 10, 2022 (GLOBE NEWSWIRE) — Get 33% off for a limited time on our uniquely designed opportunity and strategy market research reports. Contact us today and develop winning strategies!

According The Business Research Company’s research report on hand surgical instruments market, an increase in the geriatric population is driving the handheld surgical instruments market. The geriatric population is made up of adults aged 65 and over. People at this age are more likely to get sick and catch a serious illness that requires proper treatment and surgery. Surgical instruments are used in surgeries and treatment of various diseases. For example, according to a report by the United Nations on the aging of the world population 2020, an intergovernmental organization based in the United States, the aging of the world population in 2020 was approximately 727 million people aged over 65 and is expected to reach 1.5 billion in 2050. Across the world, there is an increase in the population over 65 years of age which stood at 9.3% in 2020 and is expected to reach 16.0% by 2050. Hence, increasing geriatric population will propel the handheld surgical instruments market.

Request a sample of the global hand surgical instruments market report

The global market for hand-held surgical instruments should go from $4.83 billion in 2021 to $5.18 billion in 2022 at a compound annual growth rate (CAGR) of 7.35%. The Russian-Ukrainian war has disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions against several countries, a spike in commodity prices and supply chain disruptions, affecting many markets around the world. The Hand Surgical Instruments Market is Expected to Reach $7.00 billion in 2026 at a compound annual growth rate (CAGR) of 7.78%.

Technological advancement is a key trend that is gaining popularity in the portable surgical instruments market. Major players in the portable surgical instruments market are adopting smart surgical instruments to treat various diseases. Smart surgical instruments are advanced, user-friendly tools that save time and money. For example, in November 2021, OrthAlign, a US-based medical equipment manufacturer, introduced a new handheld smart surgical instrument called Lantern for full and partial knee replacements. The solution offers streamlined workflows to reduce OR wait times and support many ORs at once without requiring the investment in hardware or preoperative imaging required by various assisted surgical systems by computer.

Major players in the hand-held surgical instruments market are Johnson & Johnson, B Braun Melsungen AG, Medtronic, Zimmer Biomet Holdings, KLS MARTIN GROUP, Integra LifeSciences Corporation, Smith & Nephew, Aspen Surgical, CooperSurgical Inc, Thompson Surgical Instruments Inc, Becton Dickinson and Company, Swann-Morton Ltd, Peters Surgical, Huaiyin Medical Instruments CoLtd and CONMED Corporation.

The global market for hand-held surgical instruments is segmented by product into pliers, retractors, dilators, grippers, scalpels, others; by application in neurosurgery, cardiovascular, orthopedic, plastic and reconstructive surgery, obstetrics and gynecology, others; by the end user in clinics, outpatient surgical centers, etc.

North America was the greater region in the hand-held surgical instruments market in 2021. Asia Pacific should be the fastest growing region in the forecast period. Regions covered in the Portable Surgical Instruments market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Global Portable Surgical Instruments Market Report 2022 – Global Market Size, Trends and Forecast 2022-2026 is part of a series of new reports from The Business Research Society which provides the forecasted Surgical Instruments market size and growth, Surgical Instruments Market segments and geographies, Surgical Instruments market trends, drivers and restraints, revenue, profiles and shares. of key competitors in more than 1,000 industry reports, covering more than 2,500 market segments and 60 geographies.

The report also gives an in-depth analysis of the impact of COVID-19 on the market. The reports are based on 150,000 datasets, extensive secondary research and proprietary insights from interviews with industry leaders.

A highly experienced and expert team of analysts and modellers provide market analysis and forecasts. The reports identify key countries and segments for opportunities and strategies based on market trends and key competitor approaches.

Not the market you are looking for? See similar market intelligence reports:

Surgical sutures And Global Staples Market Report 2022 – By Type (Surgical Sutures, Surgical Staples), By End User (Hospitals, Ambulatory Surgical Centers (ASCs), Clinics), By Surgical Sutures (Absorbable, Non-Absorbable), By Surgical Staples (Staplers) Disposable Surgical Staplers, Reusable Surgical Staplers) – Global Market Size, Trends and Forecast 2022-2026

Global Minimally Invasive Surgical Instruments Market Report 2022 – By Product (Portable Instruments, Inflation Systems, Cutting Instruments, Guiding Devices, Electrosurgical Devices, Auxiliary Instruments), By Type of Procedure Perspective (Robotic, Non-Robotic) , By Application (Cardiothoracic Surgery, Gastrointestinal Surgery, Orthopedic Surgery, Gynecological Surgery, Cosmetic & Bariatric Surgery, Vascular Surgery, Urological Surgery), By End User (Hospitals, Outpatient Surgical Clinics, Research Institutes) – Market Size, Trends and global forecasts 2022-2026

Global Surgical Equipment Market Report 2022 – By Type (Surgical Sutures And Staples, Portable Surgical Devices & Equipment, Electrosurgical Devices & Equipment), By End User (Hospitals & Clinics, Diagnostic Laboratories), By Type of Spending (Public, Private), By Product (Instruments/Equipment, Disposables) – Market Size , trends , and global forecasts 2022-2026

Want to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in business, market and consumer research. Located around the world, it has consultants specializing in a wide range of industries, including manufacturing, healthcare, financial services, chemicals and technology.

The most comprehensive database in the world

The flagship product of the Business Research Company, Global market model, is a market information platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess gaps between supply and demand.

        
]]>
EPA to Host Meeting on Carcinogen Gases Used by Groveland Sterilization Facility – Orlando Sentinel https://canonprinterhelpdesk.com/epa-to-host-meeting-on-carcinogen-gases-used-by-groveland-sterilization-facility-orlando-sentinel/ Tue, 08 Nov 2022 10:01:58 +0000 https://canonprinterhelpdesk.com/epa-to-host-meeting-on-carcinogen-gases-used-by-groveland-sterilization-facility-orlando-sentinel/ An industrial facility in Groveland using carcinogen gas has been classified by federal authorities as posing high risk to nearby residents and is expected to be the subject of a virtual public meeting on Thursday. Under pressure from health and environmental groups, the US Environmental Protection Agency plans to tighten regulations on the use of […]]]>

An industrial facility in Groveland using carcinogen gas has been classified by federal authorities as posing high risk to nearby residents and is expected to be the subject of a virtual public meeting on Thursday.

Under pressure from health and environmental groups, the US Environmental Protection Agency plans to tighten regulations on the use of colorless and normally odorless ethylene oxide.

The Sampey Road International Sterilization Laboratory in Groveland uses ethylene oxide to sterilize medical equipment.

“EPA is reaching out to communities facing the highest risks from commercial sterilization facilities,” the agency said in announcing a public meeting at 6 p.m. Thursday.

Go to epa.gov/hazardous-air-pollutants-ethylene-oxide to register. Click on “High-Risk Locations” and then on “Groveland” to access “Register to Learn More”.

The International Sterilization Lab, opened in the 1990s, meets all current EPA requirements for the use of ethylene oxide, said company vice president Mike Walter.

“Any changes made by the EPA in the future, the International Sterilization Laboratory plans to meet these requirements,” Walter said.

Ethylene oxide is used for the sterilization of equipment that is too sensitive to water or heat. Some environmental groups want the chemical phased out. But the EPA says it is committed to addressing risks in a “comprehensive way that ensures facilities can operate safely in communities while providing sterilized medical supplies.”

In 2016, the EPA determined that the chemical was more dangerous than previously thought and declared it a carcinogen. The federal environment agency calls the chemical EtO.

“Scientific evidence in humans indicates that exposure to EtO over many years increases the risk of white blood cell cancers, including non-Hodgkin’s lymphoma, myeloma, and lymphocytic leukemia,” the agency says on its website for the presentation of ethylene oxide. “Studies also show that long-term exposure to EtO increases the risk of breast cancer in women.”

The EPA lists factories in 33 states that use ethylene oxide for sterilization of medical equipment. In August, the agency revealed that of 100 factories examined, 23 pose high risks to nearby residential communities.

These include the Groveland company, the only one in Florida, and four in Puerto Rico in Añasco, Fajardo Salinas and Villalba.

Although emissions from the 23 plants do not pose a threat under “short-term health benchmarks,” according to the EPA, “the concern is that lifetime exposure to EtO emissions could have long-term effects on health”.

The area around the International Sterilization Laboratory in Groveland is largely industrial, but is near a tractor supply and a pizza place along State Route 50.

recent news

recent news

As it happens

Be the first to know with email alerts on the latest important news from the Orlando Sentinel Newsroom.

There are residential streets south of the sterilization plant that are indicated by an EPA map as being in the area at higher risk for ethylene oxide emissions.

In announcing Thursday’s public meeting, the EPA described the Groveland company as “equipped with wet scrubbers to remove EtO from its sterilization chambers and vent room exhaust.”

“The facility is evaluating plans to reduce the amount of EtO needed for certain sterilization cycles,” the EPA statement added. “There has been no recent expansion of control equipment, but the facility is evaluating how to improve its operations to control fugitive emissions.”

Walter said the exposure risks presented by the EPA are based on modeling or computerized estimation and not actual emissions monitoring. He also said more advanced equipment to control ethylene oxide emissions is available, but it doesn’t make sense to acquire this equipment without the EPA determining new standards first. of emissions.

Walter said company officials are frustrated that the public may perceive the EPA’s actions on ethylene oxide as suggesting illegal pollution.

“We meet anything the EPA wants us to meet,” he said.

kspear@orlandosentinel.com

]]>
Fifth CIIE to welcome more participants https://canonprinterhelpdesk.com/fifth-ciie-to-welcome-more-participants/ Sat, 05 Nov 2022 20:41:00 +0000 https://canonprinterhelpdesk.com/fifth-ciie-to-welcome-more-participants/ SHANGHAI–(BUSINESS WIRE)–The CIIE, which has been widely hailed as the premier platform for foreign companies to tap into China’s endless market opportunities, will be held in Shanghai for the fifth time from Nov. 5 to 10. A total of 145 countries, regions and international organizations have confirmed their participation, according to Sun Chenghai, deputy director […]]]>

SHANGHAI–()–The CIIE, which has been widely hailed as the premier platform for foreign companies to tap into China’s endless market opportunities, will be held in Shanghai for the fifth time from Nov. 5 to 10.

A total of 145 countries, regions and international organizations have confirmed their participation, according to Sun Chenghai, deputy director general of the CIIE Bureau, who made the remarks at a press conference on Nov. 1.

The world’s first import-themed trade fair launched in 2018, the expo will once again include a trade expo, a national expo and the Hongqiao International Economic Forum.

Eight countries – Nicaragua, Djibouti, Mauritania, Comoros, Mozambique, Democratic Republic of Congo, Iraq and Iceland – will participate in the national exhibition for the first time.

In addition, all member states of the Regional Comprehensive Economic Partnership will have enterprises participating in the expo.

A total of 284 of the world’s top 500 companies and industry giants will be present at the trade show, and hundreds of new products, technologies and services will be exhibited in the six main exhibition areas – food and agricultural products , smart industry and information technology, medical equipment and healthcare products, consumer goods, trade in services and automobiles, Sun said.

In line with the country’s 14th Five-Year Plan (2021-25) and goals to 2035, the event established special subsections for crop seed industry and artificial intelligence, optimized the special subsection for low-carbon energy and environmental protection technology, and expanded the innovation and incubation subsection. More than 150 startups specializing in technological equipment, consumer products and the medical and automotive fields will present their products and services at the innovation and incubation subsection.

An integral part of the CIIE, this year’s Hongqiao International Economic Forum will focus more on topics related to global opening-up, with the number of sub-forums increasing from 14 to 24.

Some parallel sessions will be co-hosted by ministries and commissions, think tanks and a number of international organizations, including the United Nations Industrial Development Organization, the United Nations Population Fund, the Compact world of the United Nations, etc. Five of these forums have keynote speeches given by Nobel laureates.

Nearly 20 authoritative reports, including the Global Openness Report 2022will be published during the forum.

]]>
Welcoming abortion patients where they are: providers turn to mobile units https://canonprinterhelpdesk.com/welcoming-abortion-patients-where-they-are-providers-turn-to-mobile-units/ Wed, 02 Nov 2022 21:46:28 +0000 https://canonprinterhelpdesk.com/welcoming-abortion-patients-where-they-are-providers-turn-to-mobile-units/ LaQuetta Cooper stands in front of a large blue RV parked in an industrial lot across the Mississippi River from St. Louis. It looks a lot like any other motorhome on the road – except for the lettering on the side that says “Mobile Health Clinic”. A chapter of Planned Parenthood operating in Missouri and […]]]>

LaQuetta Cooper stands in front of a large blue RV parked in an industrial lot across the Mississippi River from St. Louis. It looks a lot like any other motorhome on the road – except for the lettering on the side that says “Mobile Health Clinic”.

A chapter of Planned Parenthood operating in Missouri and Illinois is preparing to open a mobile unit offering abortions in southern Illinois.

Sarah McCammon/NPR

Cooper, director of health care operations for Planned Parenthood of the St. Louis and Southwest Missouri Region, said the vehicle will soon offer abortion pills to Illinois patients, reducing their commute times. approaching them.

“The biggest needs we see are the fact that they have to travel so far to get the care they need,” Cooper said. “It will be useful so that they don’t have to travel three to five hours.”

The RV was delivered this week for a launch in the coming months. Family planning first announced his project to develop unity about a month ago.

Meet patients closer to home

Since the U.S. Supreme Court’s June ruling overturning abortion rights precedent Roe vs. WadeCooper says thousands of patients flocked at the organization’s clinic in southern Illinois after their states have enacted bans on the procedure.

“I didn’t think other states” [abortion rights] would be overthrown so quickly,” she said. “Because of that, we’ve seen a huge uptick, faster than we thought, over the past few months.

As a result, Planned Parenthood officials said they wanted to find a way to expand capacity and make it easier for patients in abortion-banning states to reach them. Many struggle to take time off work, find childcare and cover the cost of travel long distances for appointments.

Planned Parenthood’s new mobile clinic will operate in Illinois, where abortion remains legal, but may move closer to other states.

Inside, the clinic is equipped with two examination rooms – including small examination tables and ultrasound machines. It is one of the few such units across the country that are set up to provide abortions.

Planned Parenthood, including Dr. Colleen McNicholas, left, and LaQuetta Cooper, right, tour staff at the new mobile clinic that will soon provide abortion pills to patients in Illinois.

Planned Parenthood, including Dr. Colleen McNicholas, left, and LaQuetta Cooper, right, tour staff at the new mobile clinic that will soon provide abortion pills to patients in Illinois.

Sarah McCammon/NPR

Around the time of the Supreme Court’s decision, the nonprofit Just the Pill quietly began offering abortion pills in a similar setup in Colorado. Since then, Dr. Julie Amaon, the medical director, says more than 100 patients have received abortion pills from this clinic. She says the ability to move around offers several benefits – especially in the current legal and political climate.

“We can go where the need is greatest, which means less travel for our patients, it means we can adapt quickly to courts, state legislatures and markets,” says Amaon. -up clinics – whatever the next iteration is – is just one thing we’re going to do…to help expand access.”

In addition to offering abortion pills through the mobile clinic in Colorado, Amaon says her organization offers telehealth assessments and mail-in prescriptions to patients in several other states.

Changing rules, changing strategies

With the annulment of Roe v. Wade, anti-abortion rights groups are urging midterm voters to choose candidates who will ban abortion in their states.

Reagan Barklage, national field director for Students for Life of America, is based in the St. Louis area. She says she would like to see lawmakers work to prevent patients in abortion-banning states from seeking the procedure elsewhere.

“I know there are lawmakers working on bills that would prevent women from crossing state lines,” Barklage said. “They’re trying to come up with different strategies to work on that and also ways to stop women from buying [pills] on line.”

Two small examination rooms inside the mobile clinic include examination tables and medical equipment.

Two small examination rooms inside the mobile clinic include examination tables and medical equipment.

Sarah McCammon/NPR

Balancing safety, security and the law

Barklage, whose group promotes anti-abortion candidates and legislation through door-to-door campaigns and lobbying in state capitals, says she is concerned about the safety of patients taking pills. at home.

This concern is unwarranted, says Amaon, who notes that medical abortion has been approved by the Food and Drug Administration over 20 years agoand claims that its mobile patients receive the same assessment and follow-up care as other patients at other clinics or hospitals.

Mobile clinics will operate in the same complex legal landscape as other abortion providers, with a patchwork of different laws from state to state, says Dr. Carole Joffe, a sociologist at the University of California, San Francisco, specializing in reproductive health.

Joffe describes himself as cautiously optimistic that mobile clinics could help close some of the distance for abortion patients in places with new restrictions.

“The reason for my caution, as well as my optimism, is that abortion healthcare is unlike any other branch of healthcare.” Joffe said. “Any initiative taken to increase access to abortion will be welcomed by those who oppose abortion in an attempt to hinder it in various ways.”

Joffe also points to security issues – which can be particularly heightened for mobile units.

It’s also a concern for Just the Pill, according to Amaon, who says the mobile clinic has hired security personnel and installed bullet-proofs in the vans, as a precaution.

“We look at the same issues as a brick and mortar [clinic] would,” she said. “Where can we park our clinic, where we can feel safe where patients don’t have to meet protesters – or if they do, they have a safe route to get there.

Amaon says they pre-screen patients before scheduling an in-person visit and reveal the exact meeting location on the day of the appointment. Planned Parenthood says its new unit is developing similar protocols to protect patient and staff safety.

A potential model in a post-deer world

Dr. Colleen McNicholas, Planned Parenthood’s chief medical officer for the St. Louis and southwestern Missouri area, says she thinks the mobile clinic could be replicated in other parts of the country where neighboring states restrict abortion:

“This unit is really, for us, a demonstration of an act of defiance,” she said. “We’re here, and we’re going to be here, and we’re going to keep showing up for the people who need us.”

Planned Parenthood plans to begin offering abortion pills from the mobile unit later this year and surgical abortions sometime next year, focusing on patients in southern Illinois. Just the Pill has purchased a second mobile clinic and plans to open a third. The group also plans to offer surgical abortions next year and plans to expand from Colorado to Illinois and Minnesota.

Copyright 2022 NPR. To learn more, visit https://www.npr.org.

]]>
FLEX LTD. MANAGEMENT REPORT AND ANALYSIS OF FINANCIAL POSITION AND OPERATING RESULTS (Form 10-Q) https://canonprinterhelpdesk.com/flex-ltd-management-report-and-analysis-of-financial-position-and-operating-results-form-10-q/ Mon, 31 Oct 2022 10:06:11 +0000 https://canonprinterhelpdesk.com/flex-ltd-management-report-and-analysis-of-financial-position-and-operating-results-form-10-q/ Unless otherwise specified, references in this report to “Flex”, “the company”, “we”, “us”, “our” and similar terms mean Flex Ltd. and its subsidiaries. This report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, […]]]>

Unless otherwise specified, references in this report to “Flex”, “the company”, “we”, “us”, “our” and similar terms mean Flex Ltd. and its subsidiaries.


This report on Form 10-Q contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended, and
Section 27A of the Securities Act of 1933, as amended. The words "expects,"
"anticipates," "believes," "intends," "plans" and similar expressions identify
forward-looking statements. In addition, any statements which refer to
expectations, projections or other characterizations of future events or
circumstances are forward-looking statements. We undertake no obligation to
publicly disclose any revisions to these forward-looking statements to reflect
events or circumstances occurring subsequent to filing this Form 10-Q with the
Securities and Exchange Commission (the "SEC"). These forward-looking statements
are subject to risks and uncertainties, including, without limitation, those
risks and uncertainties discussed in this section, as well as any risks and
uncertainties discussed in Part I, Item 1A, "Risk Factors" and in
Part II, Item 7, "Management's Discussion and Analysis of Financial Condition
and Results of Operations" in our Annual Report on Form 10-K for the fiscal year
ended March 31, 2022. In addition, new risks emerge from time to time and it is
not possible for management to predict all such risk factors or to assess the
impact of such risk factors on our business. Accordingly, our future results may
differ materially from historical results or from those discussed or implied by
these forward-looking statements. Given these risks and uncertainties, the
reader should not place undue reliance on these forward-looking statements.

OVERVIEW


We are the diversified manufacturing partner of choice that helps market-leading
brands design, build and deliver innovative products that improve the world.
Through the collective strength of a global workforce across approximately 30
countries with responsible, sustainable operations, we deliver advanced
manufacturing solutions and operate one of the most trusted global supply
chains, supporting the entire product lifecycle with fulfillment, after-market,
and circular economy solutions for diverse industries including cloud,
communications, enterprise, automotive, industrial, consumer devices, lifestyle,
healthcare, and energy. Our three operating and reportable segments are:

• Flex Agility Solutions (“FAS”), which includes the following end markets:

• Communications, Enterprise and Cloud, including data infrastructure, edge infrastructure and communications infrastructure;

•Lifestyle, including appliances, consumer packaging, floor care, micro-mobility and audio; and

•Consumer devices, including mobile and high-speed consumer devices.

• Flex Reliability Solutions (“FRS”), which includes the following end markets:

• Automotive, including next-generation mobility, autonomy, connectivity, electrification and smart technologies;

• Healthcare solutions, including medical devices, medical equipment and drug delivery; and

•Industrial, including capital goods, industrial appliances, renewables and network edge.


•Nextracker, the leading provider of intelligent, integrated solar tracker and
software solutions used in utility-scale and ground-mounted distributed
generation solar projects around the world. Nextracker's products enable solar
panels to follow the sun's movement across the sky and optimize plant
performance.

Our strategy is to provide customers with a full range of competitive, vertically integrated global supply chain solutions through which we can design, build, ship and service a complete product for our customers. This enables our customers to leverage our supply chain solutions to meet their product requirements throughout the product life cycle.


Over the past few years, we have seen an increased level of diversification by
many companies, primarily in the technology sector. Some companies that have
historically identified themselves as software providers, Internet service
providers or e-commerce retailers have entered the highly competitive and
rapidly evolving technology hardware markets, such as mobile devices, home
entertainment and wearable devices. This trend has resulted in a significant
change in the manufacturing and supply chain solutions requirements of such
companies. While the products have become more complex, the supply chain
solutions required by such companies have become more customized and demanding,
and it has changed the manufacturing and supply chain landscape significantly.

We use a portfolio approach to manage our extensive service offerings. As our
customers change the way they go to market, we have the capability to reorganize
and rebalance our business portfolio in order to align with our customers' needs
and

                                       27

————————————————– ——————————

Contents


requirements in an effort to optimize operating results. The objective of our
business model is to allow us to be flexible and redeploy and reposition our
assets and resources as necessary to meet specific customers' supply chain
solution needs across all the markets we serve and earn a return on our invested
capital above the weighted average cost of that capital.

We believe that our continued business transformation to improve our portfolio
mix is strategically positioning us to take advantage of the long-term, future
growth prospects for outsourcing of advanced manufacturing capabilities, design
and engineering services and after-market services.

Update on the impact of COVID-19, component shortages and logistical constraints on our business


With the second wave of the global pandemic including follow-on variants of
COVID-19, there have been renewed disease control measures being taken to limit
the spread including movement bans and shelter-in-place orders. Although not
materially impacting our results for the first half of fiscal year 2023, with
the lockdowns in China, we experienced temporary plant closures and/or
restrictions at certain of our manufacturing facilities in China. We continue to
closely monitor the situation in all the locations where we operate. Our
priority remains the welfare of our employees. In addition, our end markets
continue to be impacted by the global supply chain disruptions. Component
shortages and logistical constraints are pervasive across the entire value
chain. We expect persistent waves of COVID-19 to remain a headwind into the near
future. Component shortages and significantly increased logistic costs are also
expected to persist at least in the near future. We continue to carefully
monitor potential supply chain disruptions due to ongoing tightness in the
overall component environment. Refer to "Risk Factors - The ongoing COVID-19
pandemic has materially and adversely affected our business and results of
operations. The duration and extent to which it will continue to adversely
impact our business and results of operations remains uncertain and could be
material." and "-- Supply chain disruptions, manufacturing interruptions or
delays, or the failure to accurately forecast customer demand, could affect our
ability to meet customer demand, lead to higher costs, or result in excess or
obsolete inventory. We have been and continue to be adversely affected by supply
chain issues, including shortages of required electronic components." as
disclosed in Part I, "Item 1A. Risk Factors" of our Annual Report on Form 10-K
for the fiscal year ended March 31, 2022.

We continually assess our capital structure in response to the current environment and expect our current financial position, including our sources of liquidity, to be adequate to fund our future liabilities. See additional discussion in the Liquidity and Capital Resources section below.

Russian invasion of Ukraine


We continue to monitor and respond to the escalating conflict in Ukraine and the
associated sanctions and other restrictions. As of the date of this report,
there is no material impact to our business operations and financial performance
in Ukraine. The full impact of the conflict on our business operations and
financial performance remains uncertain and will depend on future developments,
including the severity and duration of the conflict and its impact on regional
and global economic conditions. We will continue to monitor the conflict and
assess the related restrictions and other effects and pursue prudent decisions
for our team members, customers, and business.

Other developments


On April 28, 2021, we announced that we confidentially submitted a draft
registration statement on Form S-1 with the SEC relating to the proposed initial
public offering of Nextracker's Class A common stock. The initial public
offering and its timing are subject to market and other conditions and the SEC's
review process, and there can be no assurance that we will proceed with such
offering or any alternative transaction. Refer to "Risk Factors - We are
pursuing alternatives for our Nextracker business, including a full or partial
separation of the business, through an initial public offering of Nextracker or
otherwise, which may not be consummated as or when planned or at all, and may
not achieve the intended benefits." as disclosed in Part I, "Item 1A. Risk
Factors" of our Annual Report on Form 10-K for the fiscal year ended March 31,
2022.

On February 1, 2022, one of our subsidiaries sold Series A Preferred Units
representing a 16.7% interest in Nextracker to TPG Rise for an aggregate
purchase price of $500 million. The sale of the 16.7% interest in Nextracker
reflects an implied value for Nextracker as of the date of the sale of
$3.0 billion. See Note 7 to the consolidated financial statements in our Annual
Report on Form 10-K for the fiscal year ended March 31, 2022 for further
information.

This Quarterly Report on Form 10-Q for the fiscal quarter ended September 30,
2022 does not constitute an offer to sell or a solicitation of an offer to buy
securities, and shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of that jurisdiction.

                                       28

————————————————– ——————————

Contents

Company Overview


We are one of the world's largest providers of global supply chain solutions,
with revenues of $15.1 billion for the six-month period ended September 30, 2022
and $26.0 billion in the fiscal year ended March 31, 2022. We have established
an extensive network of manufacturing facilities in the world's major consumer
and enterprise markets (Asia, the Americas, and Europe) to serve the growing
outsourcing needs of both multinational and regional customers. We design,
build, ship, and service consumer and enterprise products for our customers
through a network of over 100 facilities in approximately 30 countries across
four continents. We also provide intelligent, integrated solar tracker and
software solutions used in utility-scale and ground-mounted distributed
generation solar projects around the world. The following tables set forth the
relative percentages and dollar amounts of net sales by region and by country,
and net property and equipment by country, based on the location of our
manufacturing sites (amounts may not sum due to rounding):

                                                          Three-Month Periods Ended                                                     Six-Month Periods Ended
                                             September 30, 2022                      October 1, 2021                   September 30, 2022                       October 1, 2021
                                                                                                       (In millions)
Net sales by region:
Americas                            $      3,459                    45  %       $  2,605            42  %       $      6,774                45  %       $        5,184            41  %
Asia                                       2,751                    35  %          2,347            38  %              5,268                35  %                4,712            37  %
Europe                                     1,556                    20  %          1,277            20  %              3,071                20  %                2,675            22  %
                                    $      7,766                                $  6,229                        $     15,113                            $       12,571

Net sales by country:
China                               $      1,770                    23  %       $  1,547            25  %       $      3,354                22  %       $        3,078            24  %
Mexico                                     1,601                    21  %          1,240            20  %              3,156                21  %                2,460            20  %
U.S.                                       1,294                    17  %            846            14  %              2,511                17  %                1,722            14  %
Malaysia                                     633                     8  %            412             7  %              1,204                 8  %                  823             7  %
Brazil                                       547                     7  %            502             8  %              1,074                 7  %                  966             8  %
Hungary                                      330                     4  %            295             5  %                616                 4  %                  647             5  %
Other                                      1,591                    20  %          1,387            21  %              3,198                21  %                2,875            22  %
                                    $      7,766                                $  6,229                        $     15,113                            $       12,571


                                                 As of                           As of
      Property and equipment, net:         September 30, 2022              
 March 31, 2022
                                                            (In millions)
      Mexico                         $             672        31  %    $         626        29  %
      U.S.                                         371        17  %              354        17  %
      China                                        323        15  %              299        14  %
      Malaysia                                     137         6  %              110         5  %
      Hungary                                      113         5  %              118         6  %
      India                                        112         5  %              129         6  %
      Other                                        473        21  %              489        23  %
                                     $           2,201                 $       2,125


We believe that the combination of our extensive open innovation platform
solutions, design and engineering services, advanced supply chain management
solutions and services, significant scale and global presence, and manufacturing
campuses in low-cost geographic areas provide us with a competitive advantage
and strong differentiation in the market for designing, manufacturing and
servicing consumer and enterprise products for leading multinational and
regional customers. Specifically, we offer our customers the ability to simplify
their global product development, manufacturing process, and after sales
services, and enable them to meaningfully accelerate their time to market and
cost savings.

Our results of operations are influenced by a number of factors, including the following:

•impacts on our business due to component shortages, transportation disruptions or other supply chain constraints, including as a result of the global COVID-19 pandemic;

•the effects of the global COVID-19 pandemic on our business and results of operations;


                                       29

————————————————– ——————————

Contents

•the evolution of the macro-economic environment and the correlative evolution of consumer demand;


•the mix of the manufacturing services we are providing, the number, size, and
complexity of new manufacturing programs, the degree to which we utilize our
manufacturing capacity, seasonal demand, and other factors;

• the effects on our business when our customers fail to market their products or when their products do not achieve wide commercial acceptance;


•our ability to achieve commercially viable production yields and to manufacture
components in commercial quantities to the performance specifications demanded
by our customers;

•the effects that current credit and market conditions (including as a result of
the COVID-19 global pandemic and the ongoing conflict between Russia and
Ukraine) could have on the liquidity and financial condition of our customers
and suppliers, including any impact on their ability to meet their contractual
obligations;

•the effects on our business of certain customers’ products having short life cycles;

•the possibility for our customers to cancel or delay orders or modify production quantities;

•the decision of our customers to choose in-house manufacturing rather than outsourcing for their product needs;

•the integration of acquired activities and facilities;

•increased labor costs due to unfavorable working conditions in the markets in which we operate;

•changes in tax legislation; and

•changes in regulations and commercial treaties.

We are also subject to other risks as discussed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2022.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES


The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America ("U.S. GAAP" or "GAAP")
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and
liabilities at the date of the financial statements, and the reported amounts of
revenues and expenses during the reporting period. Due to the COVID-19 pandemic
and the ongoing conflict between Russia and Ukraine, there has been and will
continue to be uncertainty and disruption in the global economy and financial
markets. We have made estimates and assumptions taking into consideration
certain possible impacts due to COVID-19 and the Russian invasion of Ukraine.
These estimates may change, as new events occur, and additional information is
obtained. Actual results may differ from those estimates and assumptions.

Refer to the accounting policies under Item 7, "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in our Annual Report
on Form 10-K for the fiscal year ended March 31, 2022, where we discuss our more
significant judgments and estimates used in the preparation of the condensed
consolidated financial statements.

                                       30

--------------------------------------------------------------------------------

RESULTS OF OPERATIONS


The following table sets forth, for the periods indicated, certain statements of
operations data expressed as a percentage of net sales (amounts may not sum due
to rounding). The financial information and the discussion below should be read
together with the condensed consolidated financial statements and notes thereto
included in this document. In addition, reference should be made to our audited
consolidated financial statements and notes thereto and related Management's
Discussion and Analysis of Financial Condition and Results of Operations
included in our Annual Report on Form 10-K for the fiscal year ended March 31,
2022.

                                                               Three-Month Periods Ended                                    Six-Month Periods Ended
                                                      September 30, 2022                 October 1, 2021          September 30, 2022         October 1, 2021
Net sales                                                                100.0  %                 100.0  %                   100.0  %                 100.0  %
Cost of sales                                                             92.4                     92.4                       92.5                     92.5
Restructuring charges                                                        -                      0.1                          -                      0.1
Gross profit                                                               7.6                      7.5                        7.5                      7.4
Selling, general and administrative expenses                               3.2                      3.4                        3.2                     

3.3


Intangible amortization                                                    0.2                      0.3                        0.3                      0.2
Operating income                                                           4.2                      3.8                        4.0                      3.9
Interest and other, net                                                    0.7                     (2.2)                       0.7                     

(0.9)


Income before income taxes                                                 3.5                      6.0                        3.3                     

4.8

Provision for income taxes                                                 0.4                      0.6                        0.4                      0.5
Net income                                                                 3.1  %                   5.4  %                     2.9  %                   4.3  %
Net income attributable to redeemable
noncontrolling interest                                                    0.1                        -                        0.1                     

Net income attributable to Flex Ltd.                                       3.0  %                   5.4  %                     2.8  %                   4.3  %


Net sales

The following table sets forth our net sales by segment, and their relative
percentages:

                                                                 Three-Month Periods Ended                                                      Six-Month Periods Ended
                                                     September 30, 2022                      October 1, 2021                   September 30, 2022                       October 1, 2021
                                                                                                              (In millions)
Net sales:
Flex Agility Solutions                     $      4,004                     52  %       $  3,437            55  %       $      7,995                53  %       $        6,869            55  %
Flex Reliability Solutions                        3,299                     42  %          2,465            40  %              6,268                41  %                5,047            40  %
Nextracker                                          473                      6  %            339             5  %                868                 6  %                  680             5  %
Intersegment eliminations                           (10)                     -  %            (12)            -  %                (18)                -  %                  (25)            -  %
                                           $      7,766                                 $  6,229                        $     15,113                            $       12,571


Net sales during the three-month period ended September 30, 2022 totaled $7.8
billion, representing an increase of approximately $1.5 billion, or 25% from
$6.2 billion during the three-month period ended October 1, 2021. Net sales for
our FAS segment increased approximately $0.6 billion, or 16% from the
three-month period ended October 1, 2021, primarily driven by strong
year-over-year growth in our Communications, Enterprise and Cloud (CEC) business
and a low single-digit year-over-year increase in our Lifestyle business due to
new program wins, ramps, and clear-to-build improvement. These increases in FAS
were offset by a high-teen year-over-year decrease in our Consumer Devices
business due to relatively softer market demand and a planned project completion
in the fiscal year ended March 31, 2022. Net sales for our FRS segment increased
approximately $0.8 billion, or 34% from the three-month period ended October 1,
2021, primarily driven by a strong year-over-year increase in our Industrial and
Automotive businesses and a low-teen year-over year increase in our Health
Solutions business due to strong customer demand and ramps across various end
markets coupled with incremental revenues from our Anord Mardix acquisition,
despite continued supply constraints. Net sales for our Nextracker segment
increased approximately $0.1 billion, or 40% from the three-month period ended
October 1, 2021, primarily driven by an increase in gigawatts delivered and to a
lesser extent, an increased average selling price. Net sales increased across
all regions with a $0.9 billion increase to $3.5 billion in the Americas, a $0.4
billion increase to $2.8 billion in Asia, and a $0.3 billion increase to $1.6
billion in Europe.

                                       31
--------------------------------------------------------------------------------

Net sales during the six-month period ended September 30, 2022 totaled $15.1
billion, representing an increase of approximately $2.5 billion, or 20% from
$12.6 billion during the six-month period ended October 1, 2021. Net sales for
our FAS segment increased approximately $1.1 billion, or 16% from the six-month
period ended October 1, 2021, primarily driven by strong growth in our CEC
business and a mid single-digit increase in our Lifestyle business during the
current year due to new ramps, customer expansion, continued recoveries in
consumer spending along with some effect from inflation pass-through while
overcoming challenges from supply constraints. These increases in FAS were
offset by a high-teen decrease in our Consumer Device business during the
current year due to the same factors in the three-month periods discussion
above. Net sales for our FRS segment increased approximately $1.2 billion, or
24% from the six-month period ended October 1, 2021, primarily driven by strong
increases in our Industrial and Automotive businesses, and a mid single-digit
year-over year increase in our Health Solutions business during the current year
due to strong customer demand and ramps across various end markets coupled with
incremental revenues from our Anord Mardix acquisition and the recovery of
inflationary costs, despite continued supply constraints noted above. Net sales
for our Nextracker segment increased approximately $0.2 billion, or 28% from the
six-month period ended October 1, 2021, primarily driven by an increase in
gigawatts delivered and to a lesser extent, an increased average selling price
which was in part driven by an increase in logistics costs. Net sales increased
across all regions with a $1.6 billion increase to $6.8 billion in the Americas,
a $0.6 billion increase to $5.3 billion in Asia, and a $0.4 billion increase to
$3.1 billion in Europe.

Our ten largest customers during the three and six-month periods ended
September 30, 2022 accounted for approximately 35% of net sales. Our ten largest
customers during the three and six-month periods ended October 1, 2021 accounted
for approximately 36% and 35% of net sales, respectively. No customer accounted
for more than 10% of net sales during the three and six-month periods ended
September 30, 2022 or October 1, 2021.

Cost of sales


Cost of sales is affected by a number of factors, including the number and size
of new manufacturing programs, product mix, labor cost fluctuations by region,
component costs and availability and capacity utilization.

Cost of sales during the three-month period ended September 30, 2022 totaled
$7.2 billion, representing an increase of approximately $1.4 billion, or 25%
from $5.8 billion during the three-month period ended October 1, 2021. The
higher cost of sales for the three-month period ended September 30, 2022 was
primarily driven by increased consolidated sales of $1.5 billion or 25%. Cost of
sales in FAS for the three-month period ended September 30, 2022 increased
approximately $0.5 billion, or 17% from the three-month period ended October 1,
2021, which is relatively in line with the overall 16% increase in FAS revenue
during the same period primarily as a result of higher revenue in our CEC and
Lifestyle businesses. Cost of sales in FRS for the three-month period ended
September 30, 2022 increased approximately $0.8 billion, or 34% from the
three-month period ended October 1, 2021, which is in line with the overall 34%
increase in FRS revenue during the same period, primarily as a result of higher
revenue in our Industrial and Automotive businesses. Cost of sales in our
Nextracker segment for the three-month period ended September 30, 2022 increased
approximately $0.1 billion, or 36% from the three-month period ended October 1,
2021, primarily due to the 40% increase in Nextracker revenue during the same
period partially offset by improved recovery on freight and logistics cost
increases.

Cost of sales during the six-month period ended September 30, 2022 totaled $14.0
billion, representing an increase of approximately $2.4 billion, or 20% from
$11.6 billion during the six-month period ended October 1, 2021. The higher cost
of sales for the six-month period ended September 30, 2022 was primarily driven
by increased consolidated sales of $2.5 billion or 20%. Cost of sales in FAS for
the six-month period ended September 30, 2022 increased approximately
$1.1 billion, or 16% from the six-month period ended October 1, 2021, which is
aligned with the overall 16% increase in FAS revenue during the same period
primarily due to the drivers noted in the discussion above for the three-month
period. Cost of sales in FRS for the six-month period ended September 30, 2022
increased approximately $1.1 billion, or 25% from the six-month period ended
October 1, 2021, which is relatively in line with the overall 24% increase in
FRS revenue during the same period, primarily due to the drivers noted in the
discussion above for the three-month period. Cost of sales in our Nextracker
segment for the six-month period ended September 30, 2022 increased
approximately $0.2 billion, or 25% from the six-month period ended October 1,
2021, primarily driven by the same factors noted above in the three-month
periods discussion.

Gross profit


Gross profit is affected by fluctuations in cost of sales elements as outlined
above and further by a number of factors, including product life cycles, unit
volumes, pricing, competition, new product introductions, and the expansion or
consolidation of manufacturing facilities, as well as specific restructuring
activities initiated from time to time. The flexible design of our manufacturing
processes allows us to manufacture a broad range of products in our facilities
and better utilize our manufacturing capacity across our diverse geographic
footprint and service customers from all segments. In the cases of new programs,
profitability normally lags revenue growth due to product start-up costs, lower
manufacturing program volumes in the start-up phase, operational inefficiencies,
and under-absorbed overhead. Gross margin for these programs often improves

                                       32

--------------------------------------------------------------------------------

over time as manufacturing volumes increase, our utilization rates and overhead absorption improve, and we increase the content level of manufacturing services. Due to these various factors, our gross margin varies from period to period.


Gross profit during the three-month period ended September 30, 2022 increased
$0.1 billion to $0.6 billion, or 7.6% of net sales, from $0.5 billion, or 7.5%
of net sales, during the three-month period ended October 1, 2021. Gross margin
improved 10 basis points during the three-month period ended September 30, 2022
primarily due to the overall strong customer demand across various end markets
which allowed for improved fixed cost absorption and benefits from prior
restructuring activities, despite continued pressure on margin from component
shortages, logistics constraints and the pass-through effect of inflationary
cost recoveries.

Gross profit during the six-month period ended September 30, 2022 increased $0.2
billion to $1.1 billion, or 7.5% of net sales, from $0.9 billion, or 7.4% of net
sales, during the six-month period ended October 1, 2021. Gross margin improved
10 basis points during the same period due to the same factors noted above in
the three-month periods discussion.

Segment income


An operating segment's performance is evaluated based on its pre-tax operating
contribution, or segment income. Segment income is defined as net sales less
cost of sales, and segment selling, general and administrative expenses, and
does not include intangible amortization, stock-based compensation,
restructuring charges, and legal and other. A portion of depreciation is
allocated to the respective segments, together with other general corporate
research and development and administrative expenses.

The following table sets forth segment income and margins. Segment margins in
the table below may not recalculate exactly due to rounding and are calculated
based on unrounded numbers.

                                                           Three-Month Periods Ended                                                    Six-Month Periods Ended
                                              September 30, 2022                         October 1, 2021                  September 30, 2022                  October 1, 2021
                                                                                                    (In millions)
Segment income:
Flex Agility Solutions            $        170                         4.3  %       $   153             4.5  %       $      342             4.3  %       $   290             4.2  %
Flex Reliability Solutions                 175                         5.3  %           126             5.1  %              322             5.1  %           271             5.4  %
Nextracker                                  43                         9.1  %            25             7.4  %               73             8.4  %            50             7.4  %


FAS segment margin decreased approximately 20 basis points, to 4.3%, for the
three-month period ended September 30, 2022, from 4.5% for the three-month
period ended October 1, 2021. The margin decrease was driven by elevated costs
due to component shortages and logistics constraints combined with certain
inflation pass-through recoveries. The FAS segment margin increased
approximately 10 basis point, to 4.3% for the six-month period ended
September 30, 2022, from 4.2% for the six-month period ended October 1, 2021.
The increase in FAS segment margin during the six-month period is primarily due
to strong execution against new project ramps and product mix, partially offset
by elevated costs due to component shortages and logistics constraints and the
effect of certain inflation pass-through recoveries.

FRS segment margin increased approximately 20 basis points, to 5.3% for the
three-month period ended September 30, 2022, from 5.1% for the three-month
period ended October 1, 2021. The margin increase in FRS was primarily driven by
higher margin from the Anord Mardix acquisition in our Industrial business,
coupled with logistics constraints, partially offset by production disruptions
in our Automotive and Health Solutions businesses during the three-month period
ended September 30, 2022. FRS segment margin decreased approximately 30 basis
points, to 5.1% for the six-month period ended September 30, 2022, from 5.4% for
the six-month period ended October 1, 2021. The decrease in FRS segment margin
during the six-month period was primarily driven by component shortage related
production disruptions, as well as inflationary cost pressures impacting our
Health Solutions and Automotive businesses.

Nextracker segment margin increased approximately 170 basis points, to 9.1% for
the three-month period ended September 30, 2022, from 7.4% for the three-month
period ended October 1, 2021. The margin increase was driven by improved pricing
and better cost controls and better cost absorption with increased revenue.
Nextracker segment margin increased approximately 100 basis points, to 8.4% for
the six-month period ended September 30, 2022, from 7.4% for the six-month
period ended October 1, 2021. The increase in Nextracker segment margin during
the six-month period is due to the same factors noted in the discussion above
for the three-month period.

Selling, general and administrative expenses


Selling, general and administrative expenses ("SG&A") was approximately $0.2
billion, or 3.2% of net sales, during the three-month period ended September 30,
2022, increasing $32 million from approximately $0.2 billion and improving 20
basis

                                       33
--------------------------------------------------------------------------------

points from 3.4% of net sales, during the three-month period ended October 1,
2021. SG&A was $0.5 billion, or 3.2% of net sales, during the six-month period
ended September 30, 2022, increasing $72 million from $0.4 billion and improving
10 basis points from 3.3% of net sales, during the six-month period ended
October 1, 2021, which reflects our enhanced cost control efforts to support
higher revenue growth while keeping our SG&A expenses relatively flat.

Intangible amortization


Amortization of intangible assets increased to $21 million during the
three-month period ended September 30, 2022, from $15 million for the
three-month period ended October 1, 2021, and increased to $43 million during
the six-month period ended September 30, 2022, from $30 million for the
six-month period ended October 1, 2021, primarily due to amortization expense
related to new intangible assets from the Anord Mardix acquisition completed in
December 2021.

Interest and other, net

Interest and other, net was an expense of $53 million during the three-month
period ended September 30, 2022 compared to income of $134 million during the
three-month period ended October 1, 2021, primarily due to the absence in the
three-month period ended September 30, 2022 of the $149 million gain related to
a certain tax credit recorded upon approval of a "Credit Habilitation" request
by the relevant Brazilian tax authorities in the three-month period ended
October 1, 2021 and losses from equity in earnings recognized for certain of our
non-core equity method investments, coupled with higher interest expense
compared to the prior year period.

Interest and other, net was an expense of $93 million during the six-month
period ended September 30, 2022 compared to income of $111 million during the
six-month period ended October 1, 2021, due to the same drivers noted in the
discussion above.

Income taxes

Certain of our subsidiaries, at various times, have been granted tax relief in
their respective countries, resulting in lower income taxes than would otherwise
be the case under ordinary tax rates. Refer to note 15, "Income Taxes" of the
notes to the consolidated financial statements in our Annual Report on Form 10-K
for the fiscal year ended March 31, 2022 for further discussion.

The consolidated effective tax rate was 13% and 14% for the three and six-month
periods ended September 30, 2022, and 9% and 10% for the three and six-month
periods ended October 1, 2021, respectively. The effective rate varies from the
Singapore statutory rate of 17% as a result of recognition of earnings in
different jurisdictions (we generate most of our revenues and profits from
operations outside of Singapore), operating loss carryforwards, income tax
credits, release of previously established valuation allowances for deferred tax
assets, liabilities for uncertain tax positions, as well as the effect of
certain tax holidays and incentives granted to our subsidiaries primarily in
China, Malaysia, the Netherlands and Israel. The effective tax rate for the
three and six-month periods ended September 30, 2022 were higher than the
effective tax rates for the three-month and six-month periods ended October 1,
2021 due to the changing jurisdictional mix of income and there were significant
Brazilian indirect tax credits recorded for the three and six-month periods
ended October 1, 2021 with minimal tax impact.

On August 16, 2022, the Inflation Reduction Act of 2022 ("IRA") was enacted into
law, which includes a new corporate minimum tax, a stock repurchase excise tax,
numerous green energy credits, other tax provisions, and significantly increased
enforcement resources. We are evaluating the effect the IRA will have on our
consolidated financial statements.


CASH AND CAPITAL RESOURCES


In response to the recent challenging environment following the COVID-19
pandemic, we continuously evaluate our ability to meet our obligations over the
next 12 months and have proactively reset our capital structure during these
times to improve maturities and liquidity. As a result, we expect that our
current financial condition, including our liquidity sources are adequate to
fund current and future commitments. As of September 30, 2022, we had cash and
cash equivalents of approximately $2.5 billion and bank and other borrowings of
approximately $4.0 billion. As of September 30, 2022, we had a $2.5 billion
revolving credit facility that is due to mature in July 2027 (the "2027 Credit
Facility"), under which we had no borrowings outstanding. We also entered into a
$450 million delayed draw term loan credit agreement, under which we had no
borrowings outstanding as of September 30, 2022. Borrowings under the delayed
draw term loan may be used for working capital, capital expenditures,
refinancing of current debt, and other general corporate purposes. Refer to note
6 to the condensed consolidated financial statement for details on the 2027
Credit Facility and the delayed draw term loan. As of September 30, 2022, we
were in compliance with the covenants under all of our credit facilities and
indentures.

                                       34
--------------------------------------------------------------------------------

Cash flows generated by operating activities were $0.1 billion during the six-month period ended September 30, 2022mainly motivated by $0.4 billion net income for the period plus $0.3 billion non-cash charges such as depreciation, amortization and stock-based compensation offset by changes in net working capital, as shown below.


We believe net working capital ("NWC") and net working capital as a percentage
of annualized net sales are key metrics that measure our liquidity. Net working
capital is calculated as current quarter accounts receivable, net of allowance
for doubtful accounts, plus inventories and contract assets, less accounts
payable. Net working capital increased $1.2 billion to $5.4 billion as of
September 30, 2022, from $4.2 billion as of March 31, 2022. This increase is
primarily driven by a $1.1 billion increase in inventories due to strong demand,
coupled with continued component shortages and logistics constraints, clear-to
build constraints and logistics challenges driving up buffer stock and inventory
pricing, and a $0.6 billion increase in net receivables, offset by a $0.6
billion increase in accounts payable due to increased inventory purchases. Our
current quarter net working capital as a percentage of annualized net sales for
the quarter ended September 30, 2022, increased to 17.4% from 15.4% of
annualized net sales for the quarter ended March 31, 2022 due to component
shortages, clear-to-build and logistics constraints. We continue to experience
component shortages in the supply chain, and although we are actively managing
these impacts, we expect continued working capital pressure in the near future.
We expect it will take additional time to adequately drive down our inventory
levels to align with the current demand environment. We are proactively working
with our partners to rebalance safety and buffer stock requirements and we have
an established enterprise-wide cross-functional initiative resetting our load
planning. Component shortages and significantly increased logistic costs are
also expected to persist at least in the near future. We are working diligently
with our partners to secure needed parts and fulfill demand. In addition, to the
extent possible, we have collaborated with our customers for working capital
advances to offset the required investment in inventory. Advances from customers
as of September 30, 2022 increased $0.6 billion to $2.0 billion from $1.4
billion as of March 31, 2022.

Cash used in investing activities was $0.3 billion during the six-month period
ended September 30, 2022. This was primarily driven by $0.3 billion of net
capital expenditures for property and equipment to continue expanding
capabilities and capacity in support of our expanding Automotive, Industrial,
Health Solutions, and Lifestyle businesses.

We believe adjusted free cash flow is an important liquidity metric because it
measures, during a given period, the amount of cash generated that is available
to repay debt obligations, make investments, fund acquisitions, repurchase
company shares and for certain other activities. Our adjusted free cash flow is
defined as cash from operations, less net purchases of property and equipment
allowing us to present adjusted cash flows on a consistent basis for investor
transparency. Our adjusted free cash flow for the six-month period ended
September 30, 2022 and October 1, 2021 was an outflow of $0.1 billion and an
inflow of $0.3 billion, respectively. Adjusted free cash flow is not a measure
of liquidity under U.S. GAAP, and may not be defined and calculated by other
companies in the same manner. Adjusted free cash flow should not be considered
in isolation or as an alternative to net cash provided by operating
activities. Adjusted free cash flows reconcile to the most directly comparable
GAAP financial measure of cash flows from operations as follows:

                                                                        Six-Month Periods Ended
                                                              September 30, 2022        October 1, 2021
                                                                             (In millions)
Net cash provided by operating activities                     $           141          $           514

Purchases of property and equipment                                      (296)                    (210)
Proceeds from the disposition of property and equipment                    18                        5
Adjusted free cash flow                                       $          (137)         $           309


Cash used by financing activities was $0.3 billion during the six-month period
ended September 30, 2022, which was primarily driven by $0.3 billion of cash
paid for the repurchase of our ordinary shares.

Our cash balances are generated and held in numerous locations throughout the
world. Liquidity is affected by many factors, some of which are based on normal
ongoing operations of the business and some of which arise from fluctuations
related to global economics and markets. Local government regulations may
restrict our ability to move cash balances to meet cash needs under certain
circumstances; however, any current restrictions are not material. We do not
currently expect such regulations and restrictions to impact our ability to pay
vendors and conduct operations throughout the global organization. We believe
that our existing cash balances, together with anticipated cash flows from
operations and borrowings available under our credit facilities, will be
sufficient to fund our operations through at least the next twelve months. As of
September 30, 2022 and March 31, 2022, approximately 30% and 34%, respectively,
of our cash and cash equivalents were held by foreign subsidiaries outside of
Singapore. Although substantially all of the amounts held outside of Singapore
could be repatriated under current laws, a significant amount could be subject
to income tax withholdings. We provide for tax liabilities on these amounts for
financial statement purposes, except for certain of our foreign earnings that
are considered indefinitely reinvested outside of

                                       35

--------------------------------------------------------------------------------

Singapore (approximately $1.6 billion as of March 31, 2022). Repatriation could
result in an additional income tax payment; however, for the majority of our
foreign entities, our intent is to permanently reinvest these funds outside of
Singapore and our current plans do not demonstrate a need to repatriate them to
fund our operations in jurisdictions outside of where they are held. Where local
restrictions prevent an efficient intercompany transfer of funds, our intent is
that cash balances would remain outside of Singapore and we would meet our
liquidity needs through ongoing cash flows, external borrowings, or both.

Future liquidity needs will depend on fluctuations in levels of inventory,
accounts receivable and accounts payable, the timing of capital expenditures for
new equipment, the extent to which we utilize operating leases for new
facilities and equipment, and the levels of shipments and changes in the volumes
of customer orders.

We maintain global paying services agreements with several financial
institutions. Under these agreements, the financial institutions act as our
paying agents with respect to accounts payable due to our suppliers who elect to
participate in the program. The agreements allow our suppliers to sell their
receivables to one of the participating financial institutions at the discretion
of both parties on terms that are negotiated between the supplier and the
respective financial institution. Our obligations to our suppliers, including
the amounts due and scheduled payment dates, are not impacted by our suppliers'
decisions to sell their receivables under this program. The cumulative payments
due to suppliers participating in the programs amounted to approximately
$0.4 billion and $0.8 billion for the three and six-month periods ended
September 30, 2022, respectively, and $0.3 billion and $0.6 billion for the
three and six-month periods ended October 1, 2021, respectively. Pursuant to
their agreement with one of the financial institutions, certain suppliers may
elect to be paid early at their discretion. We are not always notified when our
suppliers sell receivables under these programs. The available capacity under
these programs can vary based on the number of investors and/or financial
institutions participating in these programs at any point in time.

In addition, we maintain various uncommitted short-term financing facilities
including but not limited to a commercial paper program, and a revolving sale
and repurchase of subordinated notes established under the securitization
facility, under which there were no borrowings outstanding as of September 30,
2022.

Historically, we have funded operations from cash and cash equivalents generated
from operations, proceeds from public offerings of equity and debt securities,
bank debt and lease financings. We also have the ability to sell a designated
pool of trade receivables under asset-backed securitization ("ABS") programs and
sell certain trade receivables, which are in addition to the trade receivables
sold in connection with these securitization agreements. We may enter into debt
and equity financings, sales of accounts receivable and lease transactions to
fund acquisitions and anticipated growth as needed.

The sale or issuance of equity or convertible debt securities could result in
dilution to current shareholders. Further, we may issue debt securities that
have rights and privileges senior to those of holders of ordinary shares, and
the terms of this debt could impose restrictions on operations and could
increase debt service obligations. This increased indebtedness could limit our
flexibility as a result of debt service requirements and restrictive covenants,
potentially affect our credit ratings, and may limit our ability to access
additional capital or execute our business strategy. Any downgrades in credit
ratings could adversely affect our ability to borrow as a result of more
restrictive borrowing terms. We continue to assess our capital structure and
evaluate the merits of redeploying available cash to reduce existing debt or
repurchase ordinary shares.

Under our current share repurchase program, our Board of Directors authorized
repurchases of our outstanding ordinary shares for up to $1 billion in
accordance with the share purchase mandate approved by our shareholders at the
date of the most recent Annual General Meeting which was held on August 25,
2022. During the six-month period ended September 30, 2022, we paid $253 million
to repurchase shares under the current and prior repurchase plans at an average
price of $16.15 per share. As of September 30, 2022, shares in the aggregate
amount of $977 million were available to be repurchased under the current plan.

OBLIGATIONS AND CONTRACTUAL COMMITMENTS

Information regarding our long-term debt payments, operating lease payments, capital lease payments and other commitments is provided in Section 7, “Management’s Discussion and Analysis of Financial Condition and Results of operations” of our annual report on our Form 10-K for the fiscal year ended
March 31, 2022.


In July 2022, we entered into a new $2.5 billion credit facility which matures
in July 2027, replacing our previous $2.0 billion credit facility, under which
we had no borrowings outstanding as of September 30, 2022.

In September 2022, we entered into a $450 million delayed draw term loan credit
agreement, under which we had no borrowings outstanding September 30, 2022.
Borrowings under the delayed draw term loan may be used for working capital,
capital expenditures, refinancing of current debt, and other general corporate
purposes.

                                       36
--------------------------------------------------------------------------------

Other than the changes mentioned above, there have been no material changes to our contractual obligations and commitments as of September 30, 2022.

© Edgar Online, source Previews

]]>
Global Dental X-Ray Market Size to Grow USD 3.59 https://canonprinterhelpdesk.com/global-dental-x-ray-market-size-to-grow-usd-3-59/ Fri, 28 Oct 2022 10:30:00 +0000 https://canonprinterhelpdesk.com/global-dental-x-ray-market-size-to-grow-usd-3-59/ New York, USA, Oct. 28, 2022 (GLOBE NEWSWIRE) — According to a research report published by Spherical Insights & Consulting, the Global dental x-ray market size to grow from USD 2.32 billion in 2021 to USD 3.59 billion by 2030, at a compound annual growth rate (CAGR) of 5% over the forecast period. Dental x-ray […]]]>

New York, USA, Oct. 28, 2022 (GLOBE NEWSWIRE) — According to a research report published by Spherical Insights & Consulting, the Global dental x-ray market size to grow from USD 2.32 billion in 2021 to USD 3.59 billion by 2030, at a compound annual growth rate (CAGR) of 5% over the forecast period. Dental x-ray is another diagnostic tool that dentists use for intra-oral and extra-oral examinations. The increasing prevalence of dental disorders, technical improvements in dental imaging, and growing demand for cosmetic dentistry are the major factors driving the growth of the dental imaging market. The Asia-Pacific region is expected to witness the fastest growth during the forecast period.

Get a free sample of this report @ https://www.sphericalinsights.com/request-sample/1248

See a detailed table of contents here–

The COVID-19 pandemic has had a negative impact on credit portfolios. There has been an unprecedented rise in unemployment and disruptions to economic activity, putting a strain on the creditworthiness of customers and businesses. Central banks have taken a proactive approach by injecting liquidity into the market through lower interest rates and asset purchase programs. Managing and monitoring credit, market, liquidity, and operational risk in financial markets was difficult enough with ongoing geopolitical tensions, international trade wars, and occasional hurricanes and earthquakes. The current pandemic has forced risk managers and their teams to recalibrate old assumptions and models used to manage and monitor risk. The global impact of COVID-19 has shown that interdependence plays an important role in international cooperation. As a result, many governments have started to rush to identify, evaluate, and acquire reliable AI-powered solutions.

Analog X-ray systems segment represents the largest market size during the forecast period

On the basis of technology, the dental x-ray market is classified into analog x-ray systems and digital x-ray systems. The analog x-ray systems segment accounts for the largest market size during the forecast period. Its market share is expected to increase over the next few years. The rate of development may be due to the fact that high quality x-ray images require multiple exposures. This is why the analog X-ray segment is growing.

Intraoral X-ray segment will maintain a higher CAGR during the forecast period

Based on the procedure, the dental x-ray market is classified into intraoral X-rays and extra-oral X-rays. The intraocular X-ray segment will maintain a higher CAGR during the forecast period. Intraoral X-ray technology gives comprehensive images, allowing dentists to uncover cavities and monitor the overall health of teeth and jaws. Mouth imaging with intraoral X-rays is the most frequently used diagnostic technique in the field of dentistry.

Browse key industry information spread across 240pages with 127 market data tables and The figures & graphics of the report”Global dental x-ray market sizeShare and COVID-19 Impact Analysis by Technology (Analog X-ray Systems and Digital X-ray Systems), by Procedure (Intraoral X-rays and Extra-oral X-rays), by Application (Medicine, Cosmetic Dentistry, and Medical -legal), and by region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), analysis and forecasts 2021 – 2030.” in detail with the table of contents

Buy Now Full Report: https://www.sphericalinsights.com/checkout/1248

The medical segment is expected to maintain a higher CAGR during the forecast period.

Based on application, the dental x-ray market is categorized into Medical, Cosmetic Dentistry, and Forensic. The medical segment is expected to maintain a higher CAGR during the forecast period. Dental X-rays assess the amount of tooth decay and look for other oral disorders such as cysts or abscesses. The medical apps segment had the largest share of revenue, as it allows you to visualize the extent of certain conditions, including cavities, tumors, and fractures.

North America is estimated to account for the highest market share in 2021.

The dental x-ray market has been segmented into five major regions: Asia-Pacific, Europe, APAC, Latin America, and MEA. The expansion of the market is driven by several factors including increased focus on dental care and growing demand for various imaging technologies. Presence of qualified dentists, increasing number of patients with dental disorders and specialist dental hospitals are all contributing to the significant growth of the European market. Asia-Pacific to maintain a higher CAGR during the forecast period.

Find out before you buy this research report: https://www.sphericalinsights.com/inquiry-before-buying/1248

Key companies and recent developments: The report also provides elaborate analysis focusing on current business news and developments, including product development, innovations, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and others. This helps to assess the overall competition in the market. Key vendors in the dental x-ray market include Envista Holdings Corporation, DURR DENTAL SE, Cefla Medical Equipment, Carestream Dental LLC, Asahi Roentgen Ind. Co. Ltd, Acteon Group, 3Shape A/S, Biolase Inc, Align Technology, Inc, A-Dec, 3M Company, Zimmer Biomet Holdings, Institute Straumann, Danaher Corporation, Planmeca OY, Dentsply Sirona, MORITA Corporation, Medit Corporation, Midmark Corporation, Planmeca Group, Takara Belmont Corporation and VATECH Co Ltd. And other esteemed key players.

For more information about your target market, please contact us below:

Call: +1 303 800 4326 (USA)

Call: +91 90289 24100 (APAC)

E-mail: survey@sphericalinsights.com, sales@sphericalinsights.com

Contact us: https://www.sphericalinsights.com/contact us

Follow us: LinkedIn | Facebook | Twitter

]]>
Doctor pleads guilty to involvement in $54 million Medicare fraud scheme | Takeover bid https://canonprinterhelpdesk.com/doctor-pleads-guilty-to-involvement-in-54-million-medicare-fraud-scheme-takeover-bid/ Tue, 25 Oct 2022 20:47:28 +0000 https://canonprinterhelpdesk.com/doctor-pleads-guilty-to-involvement-in-54-million-medicare-fraud-scheme-takeover-bid/ A Texas doctor pleaded guilty today to his role in a $54 million scheme to defraud Medicare by prescribing durable medical equipment and genetic testing for cancer without ever seeing, talking to or treating patients. According to court documents, Daniel R. Canchola, 49, of Flower Mound, agreed to electronically sign orders for durable medical equipment […]]]>

A Texas doctor pleaded guilty today to his role in a $54 million scheme to defraud Medicare by prescribing durable medical equipment and genetic testing for cancer without ever seeing, talking to or treating patients.

According to court documents, Daniel R. Canchola, 49, of Flower Mound, agreed to electronically sign orders for durable medical equipment (DME) and cancer genetic tests that he knew were being used to submit more than $54 million in false and fraudulent Medicare claims. . From August 2018 to April 2019, Canchola received approximately $30 in exchange for every doctor’s prescription he signed authorizing orders for genetic tests for EMR and cancer that were not legitimately prescribed, not necessary. or unused, totaling more than $466,000 in bribes. Medicare beneficiaries for whom Canchola prescribed EMR and cancer genetic testing were targeted by telemarketing campaigns and at health fairs and pressured to undergo cancer genetic testing and receive EMR independently of medical necessity.

Canchola pleaded guilty to conspiracy to commit wire fraud. He is due to be sentenced on March 15, 2023 and faces a maximum sentence of 20 years in prison. A federal district court judge will determine any sentence after considering US sentencing guidelines and other statutory factors.

Assistant Attorney General Kenneth A. Polite, Jr. of the Justice Department’s Criminal Division; U.S. Attorney Chad E. Meacham for the Northern District of Texas; Acting Special Agent in Charge Jason E. Meadows of the Office of Inspector General of the Department of Health and Human Services (HHS-OIG) Dallas Region; and Chief William Marlowe of the Texas Attorney General’s Medicaid Fraud Control Unit (MFCU) made the announcement.

HHS-OIG and MFCU investigated the matter.

Acting Deputy Chief Brynn Schiess of the Criminal Division’s Fraud Section is prosecuting the case.

The Fraud Section leads the Criminal Division’s efforts to combat health care fraud through the Health Care Fraud Strike Force program. Since March 2007, this program, made up of 15 strike forces operating in 24 federal districts, has charged more than 4,200 defendants who have collectively billed the Medicare program more than $19 billion. Additionally, the Centers for Medicare & Medicaid Services, in conjunction with the Office of the Inspector General of the Department of Health and Human Services, is taking steps to hold providers accountable for their involvement in drug fraud schemes. Health care. More information can be found at https://www.justice.gov/criminal-fraud/health-care-fraud-unit.

]]>